Therapeutic target of bruton tyrosine kinase inhibition shows promise in chronic spontaneous urticaria and pemphigus vulgaris, indicating its potential for immune-mediated disorders.
Bruton tyrosine kinase (BTK), a member of the tyro sineprotein kinase Tec family, is a cytoplasmic, non-receptor kinase that plays a key role in numerous immunological pathways. BTK activity is particularly crucial in B-cell development, migration, and activation through B-cell receptor activation. Additionally, BTK is critical for receptor-mediated signal transduction involving Fc receptors, Toll-like receptors, and chemokine receptors. Due to its dual role in innate and adaptive immunity, BTK inhibition represents a promising therapeutic target for immune-mediated dermatological disorders. The potential applications of BTK inhibitors in dermatology have gained increasing attention, with a particular focus on the treatment of chronic spontaneous urticaria and pemphigus vulgaris.
No takes yet. Share an insight, caveat, or question.
Piros et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: